Genmab ADR [GMAB] stock is trading at $20.33, up 0.74%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GMAB shares have gain 5.28% over the last week, with a monthly amount glided 1.30%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Genmab ADR [NASDAQ: GMAB] stock has seen the most recent analyst activity on April 01, 2025, when Bernstein downgraded its rating to a Underperform. Previously, William Blair upgraded its rating to Outperform on March 11, 2025. On February 13, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $27 on the stock. Redburn Atlantic started tracking the stock assigning a Buy rating. JP Morgan downgraded its rating to Neutral for this stock on August 20, 2024. In a note dated July 15, 2024, RBC Capital Mkts upgraded an Outperform rating on this stock.
Genmab ADR [GMAB] stock has fluctuated between $17.24 and $30.06 over the past year. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. Genmab ADR [NASDAQ: GMAB] shares were valued at $20.33 at the most recent close of the market. An investor can expect a potential return of 121.35% based on the average GMAB price forecast.
Analyzing the GMAB fundamentals
Genmab ADR [NASDAQ:GMAB] reported sales of 3.23B for the trailing twelve months, which represents a growth of 18.64%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at 0.34%, Pretax Profit Margin comes in at 0.43%, and Net Profit Margin reading is 0.37%. To continue investigating profitability, this company’s Return on Assets is posted at 1.02, Equity is 0.26 and Total Capital is 1.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Genmab ADR’s Current Ratio is 5.34. Also, the Quick Ratio is 5.32, while the Cash Ratio stands at 2.14. Considering the valuation of this stock, the price to sales ratio is 3.87, the price to book ratio is 2.44 and price to earnings (TTM) ratio is 11.53.
